{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:07Z","timestamp":1787160967996,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.dsx.2014.09.010","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T17:05:35Z","timestamp":1413219935000},"page":"230-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: Desirable side-effects of antidiabetic drugs"],"prefix":"10.1016","volume":"8","author":[{"given":"Abhijit A.","family":"Ghadge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhangi M.","family":"Harke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh P.","family":"Khadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arundhati G.","family":"Diwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Pankaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omkar P.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar K.","family":"Ranjekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket A.","family":"Kuvalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2014.09.010_bib0005","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1074\/jbc.M706706200","article-title":"Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase and mammalian target of rapamycin-dependent mechanism","volume":"28","author":"Maya-Monteiro","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2014.09.010_bib0010","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1038\/ijo.2010.241","article-title":"Determinants of brown adipocyte development and thermogenesis","volume":"34","author":"Richard","year":"2010","journal-title":"Int J Obes"},{"key":"10.1016\/j.dsx.2014.09.010_bib0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/27376","article-title":"Leptin and the regulation of body weight in mammals","volume":"395","author":"Friedman","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.dsx.2014.09.010_bib0020","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/dc12-0223","article-title":"Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study","volume":"36","author":"Kim","year":"2013","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2014.09.010_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12965\/jer.140100","article-title":"Role of adiponectin in metabolic and cardiovascular disease","volume":"10","author":"Sewon","year":"2014","journal-title":"J Exerc Rehabil"},{"issue":"2","key":"10.1016\/j.dsx.2014.09.010_bib0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/dmrr.2378","article-title":"Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin","volume":"29","author":"Pham","year":"2013","journal-title":"Diab Metab Res Rev"},{"issue":"5","key":"10.1016\/j.dsx.2014.09.010_bib0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3923\/jms.2007.865.869","article-title":"Serum leptin and adiponectin in obese diabetic and non-diabetic","volume":"7","author":"Assal","year":"2007","journal-title":"J Med Sci"},{"issue":"11","key":"10.1016\/j.dsx.2014.09.010_bib0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1253\/circj.68.975","article-title":"Adiponectin as a biomarker of the metabolic syndrome","volume":"68","author":"Ryo","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.dsx.2014.09.010_bib0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/14746514020020011801","article-title":"Plasma lipids and antidiabetic agents: a brief overview","volume":"2","author":"Keidan","year":"2002","journal-title":"Br J Diabetes Vasc Dis"},{"key":"10.1016\/j.dsx.2014.09.010_bib0050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejphar.2008.02.042","article-title":"Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk","volume":"586","author":"Blanco-Colio","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dsx.2014.09.010_bib0055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO Consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2014.09.010_bib0060","doi-asserted-by":"crossref","first-page":"E930","DOI":"10.1152\/ajpendo.00522.2004","article-title":"Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue","volume":"288","author":"Rasouli","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dsx.2014.09.010_bib0065","first-page":"A217","article-title":"Effect of thiazolidinedione on gene expression in NIH3T3-L1 adipocytes","volume":"48","author":"Lin","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2014.09.010_bib0070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1517\/13543784.4.12.1299","article-title":"Thiazolidinediones","volume":"12","author":"Whitcomb","year":"1995","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.dsx.2014.09.010_bib0075","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.1074\/jbc.M311113200","article-title":"Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity","volume":"279","author":"Pajvani","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2014.09.010_bib0080","doi-asserted-by":"crossref","first-page":"25226","DOI":"10.1074\/jbc.M202489200","article-title":"The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways","volume":"277","author":"Fryer","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.dsx.2014.09.010_bib0085","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1152\/ajpendo.00453.2005","article-title":"Thiazolidinediones can rapidly activate AMP-activated protein kinase (AMPK) in mammalian tissues","volume":"291","author":"Lebrasseur","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.dsx.2014.09.010_bib0090","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3923\/jms.2006.626.630","article-title":"Hypoadiponectinaemia in Egyptian patients with type II diabetes mellitus with vascular complications","volume":"6","author":"El-Ghaffar","year":"2006","journal-title":"J Med Sci"}],"container-title":["Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402114000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402114000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T10:57:00Z","timestamp":1538132220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402114000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1871402114000873"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2014.09.010","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: Desirable side-effects of antidiabetic drugs","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2014.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Diabetes India. Published by Diabetes India All rights reserved.","name":"copyright","label":"Copyright"}]}}